Study of Biomarkers in Blood and Tumor Tissue to Predict Complications and Cancer Outcomes after Elective Colorectal Surgery

What this Trial Is About

Researchers are conducting an observational study to explore if proteomics, metabolomics, and proteoglycans can predict postoperative complications and serve as biomarkers for colorectal cancer. The study focuses on whether these biomarkers can detect anastomotic leakages, predict cancer recurrence, act as diagnostic tests, and be identified in tumor tissue. Participants include patients undergoing elective colorectal surgery or stoma closure, including those with colorectal cancer or benign colorectal diseases. Participants will undergo elective colorectal resections or colostomy reversals using either open or minimally invasive techniques. Blood samples will be collected daily from postoperative day 1 to day 4 or until discharge, with additional follow-up sampling at specific intervals up to three years for those diagnosed with cancer. Tumor biopsies will be taken from surgical specimens during the operation to analyze proteoglycans and other markers. Throughout the study, researchers will collect data from blood plasma and tissue to identify biomarkers predicting postoperative complications and cancer outcomes. Medical records will be reviewed prospectively for complications and mortality up to 90 days, and cancer recurrence will be tracked for up to four years. The study aims to correlate biomarker levels in plasma with tumor tissue and evaluate their diagnostic and monitoring potential for colorectal cancer.

Colorectal Omics and OfCS Proteoglycans